Synchronous metastatic disease is characterized by the presence of metastatic lesions, in addition to the primary tumor, at diagnosis. Investigators in South Korea demonstrated the benefit in a ...
Laborie already held a minority interest in the manufacturer of the Optilume drug-coated balloon technology for treatment of urethral strictures and benign prostatic hyperplasia (BPH). BioWorld ...
Laborie Medical Technologies has taken another step in a steady cadence of acquisitions, picking up prostate balloon treatment maker Urotronic in a deal worth up to $600 million. The transaction ...
December 16, 2025 Is the era within which a TURP was performed associated with differences in reoperation rates, specific surgical side effects, or the requirement for BPH medicat ...
PORTSMOUTH, N.H., May 13, 2024 /PRNewswire/ -- Laborie Medical Technologies Corp. (Laborie), a leading diagnostic and therapeutic medical technology company, announced positive 2-year and 5-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback